Research programme: metabotropic glutamate receptor antagonists - Novartis
Alternative Names: MPEPLatest Information Update: 04 Nov 2017
At a glance
- Originator Novartis
- Class Benzimidazoles; Nicotinic acids
- Mechanism of Action Metabotropic glutamate receptor 5 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Parkinson's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anxiety-disorders in Switzerland
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in Switzerland
- 01 Apr 2011 Preclinical development is ongoing in Switzerland